Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies

Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies

Background: With the spread of COVID-19, treatment of diseases such as multiple sclerosis (MS) should be resumed with caution due to the disease-modifying therapies (DMTs) used in this subset of patients and the immunoregulatory effects of these drugs. We aim to assess the outcome of COVID-19 infect...

Full description

Bibliographic Details
Main Authors: Masoud Etemadifar, Ramin Sami, Mehri Salari, Nahad Sedaghat, Amirhossein Akhavan Sigari, Ali Aghababaei, Mohammadreza Najafi, Donya Sheibani Tehrani
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Journal of Research in Medical Sciences
Subjects:
covid-19
disease-modifying therapies
multiple sclerosis
rituximab
Online Access:http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2021;volume=26;issue=1;spage=85;epage=85;aulast=Etemadifar

Internet

http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2021;volume=26;issue=1;spage=85;epage=85;aulast=Etemadifar

Similar Items